Aurobindo Pharma said the US FDA conducted a routine inspection of its wholly owned step-down subsidiary in the US from 17th to 21st August 2026, which concluded with four observations.
Market Samachar is a news aggregator. This article was originally published by mint - markets. Tap the button above to read the full story on their site.